Arena Pharmaceutical (ARNA) 1.78 $ARNA Arena (ARNA)

New Post Public Reply Private Reply Replies (0) Message Board

Sep 22, 2016 at 3:06 AM

Arena Pharmaceutical (ARNA) 1.78 $ARNA

Arena (ARNA) Beacon Discovery to Boost Research Platform
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 9:06AM CDT
Arena Pharmaceuticals, Inc. (ARNA) announced the formation of Beacon Discovery Inc., a private drug discovery enterprise to develop compounds that can be used for drug discovery and early-stage development.
CBM: 46.77 (+0.78), ANIP: 65.12 (+0.28), ANIK: 47.93 (+0.34), ARNA: 1.78 (+0.07)

Arena Pharmaceutics Announces Formation of Beacon Discovery
PR Newswire - Thu Sep 01, 3:30PM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the formation of Beacon Discovery Inc. ("Beacon"

, an independent, privately-held drug discovery incubator.
ARNA: 1.78 (+0.07)

Actelion (ALIOF) Uptravi Approved for PAH in Switzerland
Zacks Equity Research - Zacks Investment Research - Wed Aug 17, 7:29AM CDT
Actelion (ALIOF) announced that Uptravi was granted approval by Swissmedic for treatment of patients with pulmonary arterial hypertension (PAH).
ANIP: 65.12 (+0.28), ANIK: 47.93 (+0.34), ARNA: 1.78 (+0.07)

Arena Pharmaceuticals Announces Appointment of Vincent Aurentz as Chief Business Officer
PR Newswire - Mon Aug 15, 6:00AM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced that Vincent Aurentz will join its management team as Executive Vice President and Chief Business Officer, effective today. Mr. Aurentz will report to Amit Munshi, Arena's President and Chief Executive Officer.
ARNA: 1.78 (+0.07)

Arena's (ARNA) Q2 Loss Narrower, Revenues Increase Y/Y
Arpita Dutt - Zacks Investment Research - Tue Aug 09, 6:19AM CDT
Arena (ARNA) continues to work on the advancement of its proprietary pipeline candidates.
HSKA: 54.50 (-1.18), CBM: 46.77 (+0.78), ANIP: 65.12 (+0.28), ARNA: 1.78 (+0.07)

Arena Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update
PR Newswire - Mon Aug 08, 3:01PM CDT
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA), today reported financial results for the second quarter ended June 30, 2016, and provided a corporate update.
ARNA: 1.78 (+0.07)

Biotech Stocks Technical Report -- Arena Pharma, BIND Therapeutics, Nektar Therapeutics, and Regeneron Pharma
PR Newswire - Wed Aug 03, 7:50AM CDT
Stock-Callers.com focus is on the Biotech arena which has had an impressive performance in the last few days. On Monday, August 01, 2016, stocks within the biotech space drove the NYSE Arca Biotechnology Index up by 2.4%. Today, we review Arena Pharmaceuticals Inc. (NASDAQ: ARNA), BIND Therapeutics Inc. (NASDAQ: BIND), Nektar Therapeutics (NASDAQ: NKTR), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN). Today's research reports on the aforementioned stocks are downloadable for free upon registration at:
BIND: 0.78 (-0.09), ARNA: 1.78 (+0.07), REGN: 406.52 (+0.28), NKTR: 19.15 (+0.18)

Arena Pharmaceuticals to Release Second Quarter 2016 Financial Results and Provide Corporate Update on Monday, August 8, 2016
PR Newswire - Mon Aug 01, 3:01PM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that the Company will release its second quarter 2016 financial results and provide a corporate update on Monday, August 8, 2016, after the close of the U.S. financial markets. The Company will host a conference call and live webcast with the investment community on Monday, August 8, 2016 at 4:30 p.m. ET to discuss the financial results and provide a corporate update.
ARNA: 1.78 (+0.07)

Arena (ARNA) Q2 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Mon Aug 01, 7:56AM CDT
Will an improvement in Belviq's performance help Arena (ARNA) deliver a surprise in Q2?
FATE: 3.18 (-0.01), ARNA: 1.78 (+0.07), EXEL: 14.74 (+0.58)

How These Biotech's Stocks are Performing? - Intrexon, Vertex Pharma, Arena Pharma, and Regeneron Pharma
PR Newswire - Thu Jun 23, 6:30AM CDT
The Biotechnology industry might still be in rough waters, but it continues to present great opportunities to investors. Stock-Callers.com assesses the recent performances of our featured companies for today: Intrexon Corp. (NYSE: XON), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN). Learn more about these stocks and receive your complimentary trade alerts at:
VRTX: 91.82 (+0.13), XON: 28.11 (+0.23), ARNA: 1.78 (+0.07), REGN: 406.52 (+0.28)

Arena Pharmaceuticals Announces USAN Approval of Nonproprietary Name "Etrasimod" for its Drug Candidate APD334
PR Newswire - Mon Jun 13, 6:00AM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the United States Adopted Names (USAN) Council has approved the nonproprietary name etrasimod (pronounced Et-ras'-i-mod) for APD334, a selective oral, investigational, Sphingosine 1-Phosphate Subtype 1 (S1P1) receptor modulator with therapeutic potential in autoimmune diseases. Arena is currently studying etrasimod in a Phase 2 clinical trial for ulcerative colitis.
ARNA: 1.78 (+0.07)

Orexigen Stock Gains More than 50% on Markman Hearing
Arpita Dutt - Zacks Investment Research - Thu Jun 09, 7:58AM CDT
Orexigen's (OREX) shares shot up on a favorable Markman hearing in the Contrave patent infringement lawsuit.
OREX: 3.62 (+0.06), RTRX: 23.75 (+0.33), VVUS: 1.09 (+0.03), ARNA: 1.78 (+0.07)

Arena Pharmaceuticals (ARNA) Shares March Higher, Can It Continue?
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 9:51AM CDT
As of late, it has definitely been a great time to be an investor in Arena Pharmaceuticals, Inc. (ARNA)
ARNA: 1.78 (+0.07)

Arena's (ARNA) Q1 Loss Narrower but Revenues Fall Short
Arpita Dutt - Zacks Investment Research - Tue May 10, 7:27AM CDT
Sales of Arena's (ARNA) obesity treatment, Belviq, remain lackluster.
HSKA: 54.50 (-1.18), CBM: 46.77 (+0.78), ANIP: 65.12 (+0.28), ARNA: 1.78 (+0.07)

Arena Pharmaceuticals reports 1Q loss
Automated Insights - Mon May 09, 4:07PM CDT
SAN DIEGO (AP) _ Arena Pharmaceuticals Inc. (ARNA) on Monday reported a loss of $21.5 million in its first quarter.
ARNA: 1.78 (+0.07)

Arena Pharmaceuticals Announces Appointment of Amit D. Munshi as President and Chief Executive Officer
PR Newswire - Mon May 09, 3:05PM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it has appointed Amit D. Munshi as President, Chief Executive Officer and interim principal financial officer, effective May 11, 2016. Mr. Munshi will also join Arena's Board of Directors following Arena's 2016 annual stockholders' meeting, which is scheduled for June 13, 2016.
ARNA: 1.78 (+0.07)

Arena Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update
PR Newswire - Mon May 09, 3:05PM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported financial results for the first quarter ended March 31, 2016, and provided a corporate update.
ARNA: 1.78 (+0.07)

Drug Stocks Reporting Early Next Week: TEVA, ARNA & More
Arpita Dutt - Zacks Investment Research - Fri May 06, 8:43AM CDT
Drug companies like Teva (TEVA) and Arena (ARNA) will be reporting results early next week.
BDSI: 2.43 (+0.04), INO: 9.80 (+0.43), VVUS: 1.09 (+0.03), TEVA: 50.48 (+0.12), ARNA: 1.78 (+0.07), PBYI: 67.97 (+2.81)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

X Square's Quanta X1 Pro: CES 2027 Innovation Honoree

Leading the Charge in Embodied AI Hey, here's a wild one: X Square Robot is stepping into the limelight with its Quanta X1 Pro, rightfully snagging itself a spot as a CES Innovation Awards® 2027 Honoree. Now, before you roll your eyes and think "just another gizmo," let me walk you through why this actually matters and the ripples it might send through both tech and...

Voyageurs Park Honors Dark Skies with 2026 Recognition

Voyageurs' Skyward Triumph: A Stellar Win for Conservation Ah, the night sky. That vast, galaxy-speckled canvas we too often ignore, drowned out by urban light pollution. But hey, not in Voyageurs National Park, no sir. This gem's just snagged the 2026 International Dark Sky Place of the Year Award, handed out by those watchful folks at DarkSky International. It's a...

Spain's Young Entrepreneurs Get a Boost from Temu

Paving New Paths for Spanish Startups Temu and CEAJE are shaking hands to jumpstart a new era for Spanish entrepreneurs, promising to flip the script on digital growth and international outreach. This partnership is a big deal, aiming to leverage both parties' strengths to provide young business owners across Spain with the tools they need to ride the digital wave. A...

EBONY Celebrates Cultural Icons at 2026 Power 100 Event

Dazzling Night in Los Angeles Honors Black Excellence Step aside Oscars, last night was about powerful celebrations. EBONY threw one hell of a party with its Power 100 event at the Hollywood Palladium. This gathering wasn't just an awards ceremony—it was an explosion of culture, rhythm, and nods to a legacy that’s made waves for over 80 years. Now, what makes this...

Fields Law Firm Rallies for Toy Donations This Season

Community Spirit Kicks Off at Fields Law Firm It’s always a bright idea when companies open their doors for a good cause, especially when it involves spreading cheer to children. Over in Minnetonka, Fields Law Firm is doing just that as they jump into the holiday spirit by collecting toys for Toys for Tots through December 11. It’s a chance for everyone to get...

Galleon Forge Two Puts Europe on the AI Map

Dublin Hosts Europe's AI Sovereignty Leap If they ever told you Europe was playing catch-up in the high-tech race, someone missed the boat. Armada and Johnson Controls just put Europe right on the AI map. They're cranking up production at Galleon Forge Two in Dublin. Now we're talking about a sovereign AI infrastructure, not that rent-a-cloud deal that's been dangling...

TIER IV Unveils Open-Source AI Models for Autonomous Cars

End-to-End AI: Revolution at TIER IV Well, folks, TIER IV is shaking things up in the world of autonomous driving. They've just rolled out a bunch of end-to-end (E2E) AI models under the open-source banner of Autoware. Each model is designed to adapt to different map and sensor setups. You know, it’s like they're handing the keys of customization to developers—whether...

Yangtze River Cultural Revival: Nanjing's Bold Vision

Nanjing Hosts Cultural Dialogue on the Yangtze Right in the heart of Nanjing, there's been a buzz about preserving the past while facing the future head-on. Picture this: intellectual heavyweights from around the Yangtze basin gathering not in some plush conference room, but on the river itself. On November 10, 2026, the meeting of minds set sail, departing from Zhongshan...

Community Dental Programs Bridge Care Gaps Effectively

Community Dental Programs: A Collaborative Force for Change Kicking around the same old healthcare conundrum, aren't we? But here's the kicker—dental care, of all things, gets a fierce spotlight today. We're diving into how community dental programs, backed by the grit of professionals like Dr. Erin Beveridge Cabuling and Dr. Monica Wu, make a serious dent in improving...

DAN, GPRO, PSNL Deals Under Investor Scrutiny

Behind the Curtain: What Do These Deals Mean for Shareholders? Sometimes, investing in a stock ain't just about numbers on a screen—it's about untangling the whole messy ball of yarn these companies hand you with a smile. We're looking at Dana Incorporated (NYSE: DAN), GoPro, Inc. (NASDAQ: GPRO), and Personalis, Inc. (NASDAQ: PSNL). They've all got deals on the table,...